Cognition Therapeutics, Inc. Class of Warrant or Right, Outstanding
Cognition Therapeutics, Inc. (CGTX) had Class of Warrant or Right, Outstanding of 514.50 thousand shares as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-08-07
- 2026-06-30: Class of Warrant or Right, Outstanding 514.50K shares.
- 2026-03-31: Class of Warrant or Right, Outstanding 514.50K shares.
- 2025-12-31: Class of Warrant or Right, Outstanding 514.50K shares.
- 2025-09-30: Class of Warrant or Right, Outstanding 514.50K shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2026-06-30 | 514.50K shares 10-Q · filed 2026-08-07 |
| 2026-03-31 | 514.50K shares 10-Q · filed 2026-05-08 |
| 2025-12-31 | 514.50K shares 10-Q · filed 2026-08-07 |
| 2025-09-30 | 514.50K shares 10-Q · filed 2025-11-06 |
| 2024-12-31 | 0.00 shares 10-Q · filed 2025-11-06 |
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |